Cargando…
Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine whether abciximab (ReoPro(®)) therapy affects long-term clinical outcomes of Korean...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association of Internal Medicine
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531627/ https://www.ncbi.nlm.nih.gov/pubmed/14619381 http://dx.doi.org/10.3904/kjim.2003.18.3.129 |